2 news items
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
ACET
5 Jun 24
to demonstrate adequate safety and efficacy of Adicet's product candidates, which would prevent, delay, or limit the scope of regulatory approval
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
ACET
14 May 24
plans to commence a Phase 1 clinical trial to assess the safety and efficacy of ADI-001 in lupus nephritis in the second quarter of 2024. Preliminary
- Prev
- 1
- Next